Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells.
W. H. Palmer, L. A. Leaton, A. Campos Codo, P. S. Hume, B. Crute, M. Stone, A. van Bokhoven, R. P. Tobin, M. McCarter, W. J. Janssen, J. Roest, S. Zhu, J. Petersen, J. P. Vivian, J. Rossjohn, J. Trowsdale, A. Getahun, J. Cambier, L. Loh, P. J. Norman
Abstract
Most human killer cell immunoglobulin-like receptors (KIR) are expressed by Natural Killer (NK) cells and recognize HLA class I molecules as ligands. Uniquely, KIR3DL3 is a conserved but polymorphic inhibitory KIR recognizing a B7 family ligand, HHLA2, and is implicated for immune checkpoint targeting. Because the expression profile and biological function of KIR3DL3 remained elusive, we searched extensively for KIR3DL3 transcripts, revealing expression is highly enriched in {gamma}{delta} and CD8+ T cells rather than NK cells. These KIR3DL3 expressing cells are rare in the blood and thymus, but more common in the lungs and digestive tract. High resolution flow cytometry and single cell transcriptomics showed that peripheral blood KIR3DL3+ T cells have an activated transitional memory phenotype and are hypofunctional. The TCR usage is biased towards genes from early rearranged TCR- variable segments or V{delta}1 chains. Whereas we detected no impact of KIR3DL3 polymorphism on ligand binding, variants in the proximal promoter and at residue 86 can reduce expression. Together, we demonstrate that KIR3DL3 is upregulated in response to unconventional T cell stimulation and that individuals may vary in their ability to express KIR3DL3. These results have implications for the personalized targeting of KIR3DL3/HHLA2 checkpoint inhibition.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A novel KIR3DL2-directed CAR T-cell therapy for cutaneous and systemic T-cell lymphomas
Federico Mario Aletti, Jinsheng Weng, … Sattva S. Neelapu·bioRxiv·Nov 6, 2026
- An atlas of natural killer cell receptor expression on healthy donor T and NK lymphocytes
Stacey N. Lee, Derek Rowter, Jeanette E. Boudreau·bioRxiv·Sep 21, 2025
- The cytokine receptor DR3 identifies and activates thymic NKT17 cells
S. Luo, N. Liman, … J. H. Park·bioRxiv·Sep 27, 2021
- LAG3 marks activated but hyporesponsive NK cells.
Valeria Vasilyeva, Olivia Makinson, … Marie Marotel·European Journal of ImmunologyPeer-reviewed·Jul 1, 2025
- LILRB3 (ILT5) is a myeloid checkpoint on myeloid cells that elicits profound immununomodulation
M. Yeboah, C. Papagregoriou, … A. Roghanian·bioRxiv·Jun 4, 2020
- Inhibitory KIRs decrease HLA class II-mediated protection in Type 1 Diabetes
Laura Mora-Bitria, Johnny Debebe, … Becca Asquith·PLoS GeneticsPeer-reviewed·Dec 26, 2024